BioScrip Inc. (BIOS)

3.02
NASDAQ : Health Services
Prev Close 2.99
Day Low/High 2.97 / 3.04
52 Wk Low/High 1.35 / 3.39
Avg Volume 899.20K
Exchange NASDAQ
Shares Outstanding 127.52M
Market Cap 373.62M
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

BioScrip Announces U.S. Congress Passage Of Medicare Home Infusion Transition Benefit, Effective 2019

BioScrip Announces U.S. Congress Passage Of Medicare Home Infusion Transition Benefit, Effective 2019

BioScrip, Inc. (NASDAQ:BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced that the U.

Commit To Buy BioScrip At $2.50, Earn 23.9% Annualized Using Options

Investors considering a purchase of BioScrip Inc stock, but cautious about paying the going market price of $2.99/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the July put at the $2.50 strike, which has a bid at the time of this writing of 30 cents.

BioScrip Announces Additions To Senior Leadership Team

BioScrip Announces Additions To Senior Leadership Team

Appoints Harriet Booker as Senior Vice President, Chief Operating Officer and Danny R. Claycomb as Senior Vice President, Revenue Cycle Management

BIOS: Insiders vs. Shorts

The most recent short interest data was recently released for the 10/31/2017 settlement date, and BioScrip Inc is one of the most shorted stocks of the Russell 3000, based on 18.82 "days to cover" versus the median component at 5.18. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Short Interest Drops 11.6% For BIOS

The most recent short interest data has been released for the 08/31/2017 settlement date, which shows a 2,458,477 share decrease in total short interest for BioScrip Inc , to 18,783,163, a decrease of 11.57% since 08/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

BioScrip Applauds US House Passage Of HR3178, The Medicare Part B Improvement Act Of 2017

BioScrip Applauds US House Passage Of HR3178, The Medicare Part B Improvement Act Of 2017

Legislation Accelerates Medicare Payment of Home Infusion Therapy Services to 2019

BioScrip Announces New Senior Note Facilities

BioScrip Announces New Senior Note Facilities

Agreement Will Immediately Improve Capital Structure, Provide Operational Flexibility, and Result in Excess of $50 million in Liquidity

BIOS Crosses Above Average Analyst Target

In recent trading, shares of BioScrip Inc have crossed above the average analyst 12-month target price of $2.40, changing hands for $2.42/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

BioScrip Reports First Quarter 2017 Financial Results

Q1 Consolidated Revenue of $217.8 Million, loss from continuing operations net of income taxes of $19.0 million and Adjusted EBITDA of $5.2 Million

BioScrip Announces CFO Transition

Appoints Stephen M. Deitsch as Senior Vice President, Chief Financial Officer and Treasurer

BioScrip Announces Meeting With Investors

Company Expects Improved Profitability Following Termination of Agreement with UnitedHealthcare

Stick to Small, Fast Trades Until the Fed's out of the Way

Stick to Small, Fast Trades Until the Fed's out of the Way

Betting on negative reaction to the Fed has not worked well in the past.

BioScrip Reports Fourth Quarter And Full-Year 2016 Financial Results

Q4 Consolidated Revenue of $240.1 Million, loss from continuing operations net of income taxes of ($5.2) million and Adjusted EBITDA of $9.5 Million

TheStreet Quant Rating: D (Sell)